Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Berk, MD
Arcutis Biotherapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
92 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arcutis Clinical Site 70
Calgary, Alberta, Canada
- Arcutis Clinical Site 27
Surrey, British Columbia, Canada
- Arcutis Clinical Site 55
Winnipeg, Manitoba, Canada
- Arcutis Clinical Site 50
Fredericton, New Brunswick, Canada
- Arcutis Clinical Site 43
Ajax, Ontario, Canada
- Arcutis Clinical Site 52
London, Ontario, Canada
- Clinical Site 11
Markham, Ontario, Canada
- Clinical Site 46
Mississauga, Ontario, Canada
- Arcutis Clinical Site 46
Montréal, Ontario, Canada
- Arcutis Clinical Site 61
Peterborough, Ontario, Canada
- Arcutis Clinical Site 54
Toronto, Ontario, Canada
- Arcutis Clinical Site 39
Waterloo, Ontario, Canada
- Clinical Site 09
Windsor, Ontario, Canada
- Arcutis Clinical Site 26
Drummondville, Quebec, Canada
- Arcutis Clinical Site 45
Montreal, Quebec, Canada
- Arcutis Clinical Site 56
Montreal, Quebec, Canada
- Arcutis Clinical Site 112
Birmingham, Alabama, United States
- Arcutis Clinical Site 73
Birmingham, Alabama, United States
- Arcutis Clinical Site 63
Scottsdale, Arizona, United States
- Arcutis Clinical Site 106
Bryant, Arkansas, United States
- Arcutis Clinical Site 116
Fort Smith, Arkansas, United States
- Arcutis Clinical Site 69
Beverly Hills, California, United States
- Arcutis Clinical Site 81
Inglewood, California, United States
- Clinical Site 08
San Francisco, California, United States
- Arcutis Clinical Site 31
Santa Monica, California, United States
- Arcutis Clinical Site 130
Thousand Oaks, California, United States
- Arcutis Clinical Site 123
Centennial, Colorado, United States
- Arcutis Clinical Site 59
Coral Gables, Florida, United States
- Arcutis Clinical Site 72
Coral Gables, Florida, United States
- Arcutis Clinical Site 79
Delray Beach, Florida, United States
- Arcutis Clinical Site 103
Hollywood, Florida, United States
- Clinical Site 04
Jacksonville, Florida, United States
- Arcutis Clinical Site 15
Largo, Florida, United States
- Arcutis Clinical Site 67
Miami, Florida, United States
- Arcutis Clinical Site 68
Miami, Florida, United States
- Arcutis Clinical Site 95
Miami, Florida, United States
- Arcutis Clinical Site 29
Sanford, Florida, United States
- Clinical Site 01
Tampa, Florida, United States
- Arcutis Clinical Site 138
Wellington, Florida, United States
- Arcutis Clinical Site 47
Sandy Springs, Georgia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 Feb 2021
- Primary completion
- 28 May 2024
- Completion
- 28 May 2024
- Last update posted
- 23 Dec 2025
- Registered enrollment
- 1,220
- Registry id
- NCT04804605
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.